C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.
The Translational Therapeutics Accelerator (TRxA) by the Critical Path Institute focuses on supporting academic researchers in drug development, specifically from lab stages to patient application. TRxA offers resources, strategic guidance, and engagement with contract research organizations to help in developing data packages crucial for attracting biotechnology and pharmaceutical companies' investment in clinical trials. The TRxA BRIDGe Awards are aimed at translating early-stage novel therapeutics into Investigational New Drug (IND) supporting data packages. These projects span from early lead optimization to IND-enabling studies of small molecule therapeutics, excluding biologics, cell and gene therapies, diagnostic and medical devices, and drug repurposing initiatives. The program is open to faculty at universities and non-profit institutions worldwide, without limitation to specific therapeutic indications. It offers funding and support for three types of translational projects, each catering to different stages of drug development.